MedTrace Logo

Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa

NCT00006298 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2008-09-25

No results posted yet for this study

Summary

The main goal of this study is to find out how the immune system responds to a specific type of HIV infection, known as C HIV-1, in order to develop a vaccine against this type of infection. The study involves Southern African populations.

The HIV-1 virus changes rapidly and many different subtypes have been found. In South Africa, limited data have suggested Subtype C HIV-1 is the most common. This study strives to verify the most common subtype and also look at genetic differences and immune responses among newly infected individuals. Results will aid in the development of vaccines specific for certain geographical areas.

Conditions

  • HIV Infections
  • HIV Seronegativity

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Haynes Sheppard

  • Desmond Martin

  • Clive Gray

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006298 on ClinicalTrials.gov